Pathologic Stage IIIA Cutaneous Melanoma AJCC v8

16 clinical trials · Condition

Sort:Newest first Oldest first

◉ Watch Pathologic Stage IIIA Cutaneous Melanoma AJCC v8

Record	Firm	Date
Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors (NCT07259304)	University of Southern California	2021-11-24
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors (NCT05039801)	M.D. Anderson Cancer Center	2021-09-30
Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma (NCT04940299)	M.D. Anderson Cancer Center	2021-09-23
Bone Loss in Melanoma Survivors Receiving Immunotherapy (NCT04516122)	M.D. Anderson Cancer Center	2021-05-10
Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies (NCT04902040)	M.D. Anderson Cancer Center	2021-04-14
Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer (NCT03819296)	M.D. Anderson Cancer Center	2021-02-21
Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma (NCT04375527)	Jonsson Comprehensive Cancer Center	2020-12-03
Immune Related Toxicity and Symptom Burden in Chronic Cancer Survivors With Melanoma Receiving Adjuvant Immunotherapy With Immune Checkpoint Inhibitors (NCT04990726)	M.D. Anderson Cancer Center	2019-12-05
Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers (NCT03816332)	National Cancer Institute (NCI)	2019-11-08
Young Melanoma Family Facebook Intervention or Healthy Lifestyle Facebook Intervention in Improving Skin Examination in Participants With Melanoma and Their Families (NCT03677739)	Rutgers, The State University of New Jersey	2019-06-03
Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III Melanoma (NCT03554083)	Mayo Clinic	2018-10-05
Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1 (NCT02650986)	Roswell Park Cancer Institute	2017-07-14
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies (NCT02419495)	M.D. Anderson Cancer Center	2015-06-26

Track Pathologic Stage IIIA Cutaneous Melanoma AJCC v8 automatically

Every clearance here is in the API, with alerts when new ones post.